pimagedine has been researched along with Diabetic Neuropathies in 17 studies
pimagedine: diamine oxidase & nitric oxide synthase inhibitor; an advanced glycosylation end product inhibitor; used in the treatment of diabetic complications; structure
aminoguanidine : A one-carbon compound whose unique structure renders it capable of acting as a derivative of hydrazine, guanidine or formamide.
Diabetic Neuropathies: Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the ability of a pyridoxal-aminoguanidine adduct with both antiglycation and antioxidant activities in vitro to protect against neuropathy and cataract in streptozotocin-diabetic rats and compared the result with that of aminoguanidine." | 7.72 | Pyridoxal-aminoguanidine adduct is more effective than aminoguanidine in preventing neuropathy and cataract in diabetic rats. ( Chen, AS; Kamei, A; Miwa, I; Sugiura, M; Taguchi, T; Wakasugi, Y; Wang, MW, 2004) |
| "We examined the ability of a pyridoxal-aminoguanidine adduct with both antiglycation and antioxidant activities in vitro to protect against neuropathy and cataract in streptozotocin-diabetic rats and compared the result with that of aminoguanidine." | 3.72 | Pyridoxal-aminoguanidine adduct is more effective than aminoguanidine in preventing neuropathy and cataract in diabetic rats. ( Chen, AS; Kamei, A; Miwa, I; Sugiura, M; Taguchi, T; Wakasugi, Y; Wang, MW, 2004) |
| "Insulin sensitivity was measured using the insulin tolerance test (ITT), both in STZ diabetic and in Zucker diabetic fatty (ZDF) rats (model of type 2 diabetes)." | 1.31 | Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models. ( Bíró, K; Jednákovits, A; Kukorelli, T; Kürthy, M; Mogyorósi, T; Nagy, K; Tálosi, L, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (52.94) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Uesaka, Y | 1 |
| Guo, SS | 1 |
| Tang, DY | 1 |
| Liang, XC | 1 |
| Miyata, T | 1 |
| Kurokawa, K | 1 |
| Chen, AS | 1 |
| Taguchi, T | 1 |
| Sugiura, M | 1 |
| Wakasugi, Y | 1 |
| Kamei, A | 1 |
| Wang, MW | 1 |
| Miwa, I | 1 |
| Cameron, NE | 2 |
| Gibson, TM | 1 |
| Nangle, MR | 1 |
| Cotter, MA | 2 |
| Shotton, HR | 1 |
| Adams, A | 1 |
| Lincoln, J | 1 |
| Monnier, V | 1 |
| Gries, FA | 1 |
| Schmidt, RE | 1 |
| Dorsey, DA | 1 |
| Beaudet, LN | 1 |
| Reiser, KM | 1 |
| Williamson, JR | 1 |
| Tilton, RG | 1 |
| Monnier, VM | 1 |
| Yildiz, O | 1 |
| Ozata, M | 1 |
| Ozkardeş, A | 1 |
| Deniz, G | 1 |
| Yildirimkaya, M | 1 |
| Corakçi, A | 1 |
| Yardim, M | 1 |
| Gündoğan, MA | 1 |
| Ino-ue, M | 1 |
| Ohgiya, N | 1 |
| Yamamoto, M | 1 |
| Vinik, AI | 1 |
| Park, TS | 1 |
| Stansberry, KB | 1 |
| Pittenger, GL | 1 |
| Kürthy, M | 1 |
| Mogyorósi, T | 1 |
| Nagy, K | 1 |
| Kukorelli, T | 1 |
| Jednákovits, A | 1 |
| Tálosi, L | 1 |
| Bíró, K | 1 |
| Yagihashi, S | 1 |
| Kamijo, M | 1 |
| Baba, M | 1 |
| Yagihashi, N | 1 |
| Nagai, K | 1 |
| Kihara, M | 1 |
| Schmelzer, JD | 1 |
| Poduslo, JF | 1 |
| Curran, GL | 1 |
| Nickander, KK | 1 |
| Low, PA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)[NCT00244244] | Phase 2 | 80 participants | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for pimagedine and Diabetic Neuropathies
| Article | Year |
|---|---|
[Prevention and treatment of diabetic neuropathy].
Topics: Aldehyde Reductase; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Chronic Disease; Diabeti | 2002 |
A detective story for biomedical footprints towards new therapeutic interventions in diabetic nephropathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Glycation End Products, Advanced; G | 2003 |
Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Neuropathies; Glycation En | 2005 |
[Non-enzymatic glycosylation of proteins. Complications of diabetes mellitus, aging and kidney failure].
Topics: Aging; Arginine; Blood Glucose; Diabetes Mellitus; Diabetic Neuropathies; Glycation End Products, Ad | 1993 |
Alternative therapeutic principles in the prevention of microvascular and neuropathic complications.
Topics: Aldehyde Reductase; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Neuropa | 1995 |
Diabetic neuropathies.
Topics: Aldehyde Reductase; Animals; Diabetic Neuropathies; Enzyme Inhibitors; gamma-Linolenic Acid; Guanidi | 2000 |
11 other studies available for pimagedine and Diabetic Neuropathies
| Article | Year |
|---|---|
[Effect of wenjingtong composita on blood glucose and advanced glycosylation end products in sciatic nerve of streptozotocin-induced diabetic rats].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Drugs, Chinese Herba | 2002 |
Pyridoxal-aminoguanidine adduct is more effective than aminoguanidine in preventing neuropathy and cataract in diabetic rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Cataract; Deoxyguanosine; Diabetes Mellitus, Experimental; Dia | 2004 |
Effect of aminoguanidine treatment on diabetes-induced changes in the myenteric plexus of rat ileum.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Enzyme Inhibitors; Guanidines; Ileu | 2007 |
Effect of aminoguanidine on the frequency of neuroaxonal dystrophy in the superior mesenteric sympathetic autonomic ganglia of rats with streptozocin-induced diabetes.
Topics: Animals; Axons; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Enzyme Inhibitors; Ganglia, | 1996 |
Aminoguanidine and diabetic neuropathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Guanidines; Motor Neurons; Neural C | 1996 |
Rapid reversal by aminoguanidine of the neurovascular effects of diabetes in rats: modulation by nitric oxide synthase inhibition.
Topics: Animals; Arginine; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Angiopat | 1996 |
Comparison of the effects of aminoguanidine and L-carnitine treatments on somatosensorial evoked potentials in alloxan-diabetic rats.
Topics: Alloxan; Animals; Blood Glucose; Body Weight; Carnitine; Diabetes Mellitus, Experimental; Diabetic N | 1996 |
Effect of aminoguanidine on optic nerve involvement in experimental diabetic rats.
Topics: Animals; Body Weight; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dose-Response Relation | 1998 |
Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models.
Topics: Animals; Diabetic Neuropathies; Guanidines; Hydroxylamines; Hypoglycemic Agents; Insulin Resistance; | 2002 |
Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Glycate | 1992 |
Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals.
Topics: Action Potentials; Animals; Capillary Permeability; Diabetes Mellitus, Experimental; Diabetic Neurop | 1991 |